statins

     

Select            
Trial Studied trt Control trt patientstagsROB Trial result

cardiovascular prevention

atorvastatin
Mohler, 2003     atorvastatinplacebosecondary preventionLow risk of bias -
CARDS, 2004      NCTatorvastatinplacebodiabetic type 2 diabetes Low risk of bias conclusive
ASPEN, 2006     atorvastatinplacebodiabetic type 2 diabetes Low risk of bias negative
ASCOT, 2003   atorvastatinplaceboat risk hypertensive hypertensive patients Low risk of bias conclusive
GREACE, 2002     atorvastatinusual caresecondary preventionRisk of bias suggesting
AVERT, 1999     atorvastatin high doseangioplastysecondary preventionRisk of bias negative
TNT, 2005            NCTatorvastatin high doseatorvastatinsecondary preventionLow risk of bias conclusive
Vascular basis, 2005     atorvastatin high doselovastatinsecondary preventionExploratory negative
REVERSAL, 2004     atorvastatin high dosepravastatinsecondary preventionExploratory negative
SAGE, 2007     atorvastatin high dosepravastatinsecondary preventionExploratory suggesting
IDEAL, 2005        NCTatorvastatin high dosesimvastatinsecondary preventionRisk of bias suggesting
fluvastatin
BCAPS, 2001     fluvastatinplaceboprimary prevention cerebral vascular disease Low risk of bias negative
LIPS, 2002     fluvastatinplacebosecondary preventionLow risk of bias suggesting
LCAS, 1997     fluvastatinplacebosecondary preventionExploratory negative
Riegger et al., 1999     fluvastatinplacebosecondary preventionLow risk of bias negative
FLARE, 1999     fluvastatinplacebosecondary preventionExploratory negative
HYRIM, 2005   fluvastatinplacebohypertensive hypertensive patients Exploratory negative
lovastatin
CCAIT, 1994   lovastatinplacebosecondary preventionExploratory negative
MARS, 1993      NCTlovastatinplacebosecondary preventionExploratory negative
AFCAPS/TexCAPS, 1998     lovastatinplaceboprimary preventionLow risk of bias conclusive
Weintraub, 1994     lovastatinplacebosecondary preventionLow risk of bias negative
ACAPS, 1994    NCTlovastatinplacebosecondary prevention cerebral vascular disease Exploratory suggesting
CRISP 20mg, 1994    NCTlovastatinplacebodiabeticExploratory -
CRISP 40mg, 1994    NCTlovastatinplacebodiabeticExploratory -
Sahni, 1991   lovastatinusual caresecondary preventionRisk of bias negative
CLAPT, 1999     lovastatinusual caresecondary preventionExploratory negative
pravastatin
MEGA, 2006        NCTpravastatincontrolprimary preventionRisk of bias suggesting
FAST Fukuoka pravastatin, 2002     pravastatincontrolprimary preventionExploratory -
WOSCOPS, 1995     pravastatinplaceboprimary preventionLow risk of bias conclusive
PMSG, 1993   pravastatinplaceboprimary preventionExploratory negative
CAIUS, 1996     pravastatinplaceboprimary prevention cerebral vascular disease Exploratory negative
PROSPER (primary prevention subgroup), 2002     pravastatinplaceboprimary prevention elderly Exploratory negative
PROSPER, 2002   pravastatinplacebosecondary prevention elderly Low risk of bias conclusive
PLAC I, 1995     pravastatinplacebosecondary preventionExploratory suggesting
PLAC II, 1995     pravastatinplacebosecondary preventionExploratory negative
PACT, 2004     pravastatinplacebosecondary preventionLow risk of bias negative
LIPID, 1998         pravastatinplacebosecondary preventionLow risk of bias conclusive
CARE, 1996       pravastatinplacebosecondary preventionLow risk of bias conclusive
REGRESS, 1995       pravastatinplacebosecondary preventionExploratory suggesting
PHYLLIS, 2004     pravastatinplacebodiabetic cerebral vascular disease hypertensive patients Exploratory -
KLIS, 2000   pravastatinusual careprimary preventionRisk of bias -
GISSI Prevenzione, 2000     pravastatinusual caresecondary preventionRisk of bias negative
ALLHAT, 2002      NCTpravastatinusual careat risk hypertensive hypertensive patients Risk of bias negative
rosuvastatin
JUPITER, 2008    NCTrosuvastatinplaceboprimary preventionLow risk of bias conclusive
HOPE 3, 2016      NCTrosuvastatinplaceboprimary preventionLow risk of bias conclusive
METEOR, 2007      NCTrosuvastatinplacebodiabeticExploratory negative
simvastatin
MAAS, 1994   simvastatinplacebosecondary preventionExploratory negative
HPS, 2002         simvastatinplacebosecondary preventionLow risk of bias conclusive
4S, 1994   simvastatinplacebosecondary preventionLow risk of bias conclusive
CIS, 1997     simvastatinplacebosecondary preventionExploratory negative
HPS (diabetic primary prevention sub group), 2003     simvastatinplacebodiabetic type 2 diabetes Exploratory -
SEARCH, 2010    NCTsimvastatin high dosesimvastatinsecondary preventionLow risk of bias suggesting

heart failure

atorvastatin
Wojnicz, 2006     atorvastatincontrolheart failurenegative
Yamada, 2007     atorvastatincontrolheart failurenegative
Strey, 2005     atorvastatinplaceboheart failure -
Sola, 2006     atorvastatinplaceboheart failureLow risk of bias negative
cerivastatin
Laufs, 2004     cerivastatinplaceboheart failureLow risk of bias -
rosuvastatin
CORONA, 2007      NCTrosuvastatinplaceboheart failureLow risk of bias negative
Krum, 2007     rosuvastatinplaceboheart failureLow risk of bias negative
GISSI-HF rosuvastatine, 2008      NCTrosuvastatinplaceboheart failureLow risk of bias negative
simvastatin
Hong, 2005     simvastatincontrolheart failureRisk of bias negative
Node, 2003     simvastatinplaceboheart failurenegative
Landmesser, 2005     simvastatinezetimibeheart failure -

percutaneous coronary intervention

atorvastatin
NAPLES II (Briguori), 2009     atorvastatincontrolsuggesting
ARMYDA, 2004     atorvastatinplaceboLow risk of bias suggesting
ARMYDA-RECAPTURE, 2009   atorvastatin reloadplaceboLow risk of bias suggesting
GAIN, 2001     atorvastatinusual carenegative
fluvastatin
FLARE, 1999     fluvastatinplaceboLow risk of bias negative
LIPS, 2002     fluvastatinplaceboLow risk of bias negative
pravastatin
PREDICT, 1997     pravastatinplaceboLow risk of bias negative